glp 1 press conference Do you think GLP-1 medications should be used for addictions? @geller.endocrinology explains why we may see more of this in the future on episode 435 👀 , Comment JORDAN to get the full episode sent to GLP-1 coverage update from CMS

These evolving requirements are fostering a digitally secure infrastructure, significantly elevating the demand for blockchain solutions in the healthcare sector GLP-1 Receptor Agonists Obesity Drugs Market Analysis GLP-1 receptor agonists, a class of drugs that mimic the glucagon-such as peptide-1 hormone, are increasingly recognized as powerful therapeutic options for obesity management due to their dual benefits in appetite regulation and blood glucose control, making them essential tools in both endocrinology and weight-loss medicine The accelerating demand for GLP-1 receptor agonists is primarily driven by the global surge in obesity and type 2 diabetes cases, strong clinical outcomes demonstrating significant weight reduction, and growing medical and consumer acceptance of pharmacological obesity treatment North America dominated the GLP-1 receptor agonists obesity drugs market with the largest revenue share of 55.56% in 2024, characterized by high obesity prevalence, favorable reimbursement policies, and early adoption of innovative therapies such as semaglutide and tirzepatide, with the U.S

CBO expects the above-noted cost per user to go down as more competitors enter the market (though CBO notes that brand prices may not drop if the drugs get better as manufacturers compete on quality as well as price), more generic alternatives appear, more people use AOMs and for longer periods of time, as well as if beneficiaries who were already on AOMs prior to joining Medicare continued their treatment

Sargeant, Emma G

"So, I was 40 and feeling really good, but to be able to be 71 and feel that I am in the best shape of my life feels better than it did when I was 40." WHAT ARE GLP-3S

Kotani K, Hara K, Kotani K, Yonezawa K, Kasuga M